Appili Therapeutics (Appili Therapeutics) EV-to-EBIT : -3.24 (As of May. 25, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Appili Therapeutics's Enterprise Value is $8.54 Mil. Appili Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.64 Mil. Therefore, Appili Therapeutics's EV-to-EBIT for today is -3.24.

The historical rank and industry rank for Appili Therapeutics's EV-to-EBIT or its related term are showing as below:

APLIF' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.48 Med: -2.85 Max: 2.11
Current: -3.24

During the past 6 years, the highest EV-to-EBIT of Appili Therapeutics was 2.11. The lowest was -11.48. And the median was -2.85.

APLIF's EV-to-EBIT is ranked worse than
100% of 426 companies
in the Biotechnology industry
Industry Median: 10.295 vs APLIF: -3.24

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Appili Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $8.74 Mil. Appili Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.64 Mil. Appili Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -30.17%.

Appili Therapeutics EV-to-EBIT Historical Data

The historical data trend for Appili Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics EV-to-EBIT Chart

Appili Therapeutics Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-EBIT

Get a 7-Day Free Trial

-4.07

-3.83

-0.29

-1.24

Appili Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-1.17	-1.24	-1.52	-2.31	-3.26

Competitive Comparison of Appili Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Appili Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Appili Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Appili Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Appili Therapeutics's EV-to-EBIT falls into.

Appili Therapeutics EV-to-EBIT Calculation

Appili Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	8.543	/	-2.636
	=	-3.24

Appili Therapeutics's current Enterprise Value is $8.54 Mil.
Appili Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.64 Mil.

Appili Therapeutics (OTCPK:APLIF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Appili Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-2.636	/	8.736549
	=	-30.17 %

Appili Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $8.74 Mil.
Appili Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.64 Mil.

Appili Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Appili Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Appili Therapeutics (Appili Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

APLI:Canada

Address

1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8

Website

https://www.appilitherapeutics.com

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.